Dr. Jennifer Ruth Brown, MD, PhD

Dr. Brown practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Brown's NPI, 1457328163, was assigned on March 1, 2006. Dr. Brown graduated from Harvard Medical School in 1998. Dr. Brown holds Massachusetts license 205260.

Dr. Brown's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Brown's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Brown is also affiliated with Massachusetts General Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Brown to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Brown practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Brown's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Brown is licensed in Massachusetts.

CMS data shows 484 Medicare services from Dr. Brown across 6 procedure codes in 2024, for 268 Medicare patients. Medicare paid $39,352 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 268 Medicare patients who saw Dr. Brown in 2024. The largest group is 65 to 74, with 124 patients. 71% of them have high cholesterol, and 68% have high blood pressure. 8% are also on Medicaid. Their average risk score is 2.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Brown's median patient age at 71, with 49% women.

In 2024, Dr. Brown wrote 158 Medicare Part D claims for 54 patients. 75% of them were for generic drugs. CMS names the drug for 35 of them, across 2 drugs with 11 or more claims each, at $776 in total drug cost. In 2023, CMS named 322 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Brown for performance year 2024, reported as part of a group. Dr. Brown accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Brown as offering telehealth.

Dmand AI links Dr. Brown to 4 clinical trials. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Follicular and Neoplasm Metastasis. Open Payments lists research payments to Dr. Brown that name 4 trials.

CMS Open Payments shows 294 general payments to Dr. Brown from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. AstraZeneca Pharmaceuticals LP paid the most, $99,304. It also lists 24 research payments totaling $28,408 from 2016 to 2022, naming 4 clinical trials.

Dr. Brown graduated from Harvard Medical School in 1998.